@article{9d7893168e524c53a109206401727fdf,
title = "Host defenses against zygomycetes",
abstract = "Mucormycosis is a devastating disease and can occur in patients with a variety of risk factors, the most important of which are immunosuppression, anatomic barrier breakdown, iron overload, and hyperglycemia/acidosis. Similarly to what occurs with Aspergillus, the host stimulates an innate immune response against the challenging sporangiospores and invading hyphae of Zygomycetes. This article discusses the host defense to different Zygomycetes, its augmentation, and its subsequent impact on the outcome of mucormycosis.",
author = "Emmanuel Roilides and Kontoyiannis, {Dimitrios P.} and Walsh, {Thomas J.}",
note = "Funding Information: Potential conflicts of interest. E. R. has received grant support from Pfizer, Gilead, Enzon, Schering, and Wyeth; served as a consultant for Schering, Gilead, Astellas, and Pfizer; and served on the speakers bureaus for Gilead, Cephalon, Pfizer, Wyeth, Schering, Merck, Aventis, and Astellas. D. P. K. has received research support and honoraria from Schering-Plough, Pf izer, Astella Pharma, Enzon Pharmaceuticals, and Merck. T. J. W. has received grant support from Novartis, Astellas; Consultation: Novartis, Vestagen, iCo, Trius, Astellas, Sigma Tau, and Draius.",
year = "2012",
month = feb,
day = "1",
doi = "10.1093/cid/cir869",
language = "English (US)",
volume = "54",
pages = "S61--S66",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 1",
}